IL142537A0 - Pharmaceutical compositions for the treatment of autoimmune diseases - Google Patents

Pharmaceutical compositions for the treatment of autoimmune diseases

Info

Publication number
IL142537A0
IL142537A0 IL14253701A IL14253701A IL142537A0 IL 142537 A0 IL142537 A0 IL 142537A0 IL 14253701 A IL14253701 A IL 14253701A IL 14253701 A IL14253701 A IL 14253701A IL 142537 A0 IL142537 A0 IL 142537A0
Authority
IL
Israel
Prior art keywords
cis
unsaturated
saturated
fatty acid
treatment
Prior art date
Application number
IL14253701A
Other languages
English (en)
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Priority to IL14253701A priority Critical patent/IL142537A0/xx
Publication of IL142537A0 publication Critical patent/IL142537A0/xx
Priority to AU2002255242A priority patent/AU2002255242A1/en
Priority to PCT/IL2002/000296 priority patent/WO2002083059A2/en
Priority to DE60230067T priority patent/DE60230067D1/de
Priority to US10/474,696 priority patent/US8614248B2/en
Priority to EP02724589A priority patent/EP1480595B1/en
Priority to ES02724589T priority patent/ES2321166T3/es
Priority to IL15822802A priority patent/IL158228A0/xx
Priority to AT02724589T priority patent/ATE415157T1/de
Priority to IL158228A priority patent/IL158228A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024Esters of saccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02Local antiseptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL14253701A 2001-04-11 2001-04-11 Pharmaceutical compositions for the treatment of autoimmune diseases IL142537A0 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
IL14253701A IL142537A0 (en) 2001-04-11 2001-04-11 Pharmaceutical compositions for the treatment of autoimmune diseases
AU2002255242A AU2002255242A1 (en) 2001-04-11 2002-04-11 Use of esters of long-chain fatty acids for treatment of autoimmune diseases
PCT/IL2002/000296 WO2002083059A2 (en) 2001-04-11 2002-04-11 Use of esters of long-chain fatty acids for treatment of autoimmune diseases
DE60230067T DE60230067D1 (de) 2001-04-11 2002-04-11 Verwendung von estern langkettiger fettsäuren zur behandlung von autoimmunkrankheiten
US10/474,696 US8614248B2 (en) 2001-04-11 2002-04-11 Use of esters of long-chain fatty acids for treatment of autoimmune diseases
EP02724589A EP1480595B1 (en) 2001-04-11 2002-04-11 Use of esters of long-chain fatty acids for treatment of autoimmune diseases
ES02724589T ES2321166T3 (es) 2001-04-11 2002-04-11 Uso de esteres de acidos grasos de cadena larga para el tratamiento de enfermedades autoinmunes.
IL15822802A IL158228A0 (en) 2001-04-11 2002-04-11 Use of esters of long-chain fatty acids for treatment of autoimmune diseases
AT02724589T ATE415157T1 (de) 2001-04-11 2002-04-11 Verwendung von estern langkettiger fettsäuren zur behandlung von autoimmunkrankheiten
IL158228A IL158228A (en) 2001-04-11 2003-10-02 Use of esters of long-chain fatty acids for the preparation of medicaments for the treatment of autoimmune diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL14253701A IL142537A0 (en) 2001-04-11 2001-04-11 Pharmaceutical compositions for the treatment of autoimmune diseases

Publications (1)

Publication Number Publication Date
IL142537A0 true IL142537A0 (en) 2002-03-10

Family

ID=11075314

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14253701A IL142537A0 (en) 2001-04-11 2001-04-11 Pharmaceutical compositions for the treatment of autoimmune diseases
IL158228A IL158228A (en) 2001-04-11 2003-10-02 Use of esters of long-chain fatty acids for the preparation of medicaments for the treatment of autoimmune diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL158228A IL158228A (en) 2001-04-11 2003-10-02 Use of esters of long-chain fatty acids for the preparation of medicaments for the treatment of autoimmune diseases

Country Status (8)

Country Link
US (1) US8614248B2 (xx)
EP (1) EP1480595B1 (xx)
AT (1) ATE415157T1 (xx)
AU (1) AU2002255242A1 (xx)
DE (1) DE60230067D1 (xx)
ES (1) ES2321166T3 (xx)
IL (2) IL142537A0 (xx)
WO (1) WO2002083059A2 (xx)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003233147B2 (en) 2002-05-13 2008-03-06 Arexis Ab Autoimmune conditions and NADPH oxidase defects
ITMI20030210A1 (it) * 2003-02-07 2004-08-08 Res & Innovation Soc Coop A R L Composti endocannabinoido-simili e loro impiego
US20050032892A1 (en) * 2003-08-07 2005-02-10 The Procter & Gamble Company Compositions, kits, and methods for treating gastrointestinal conditions
US7294739B1 (en) 2006-11-06 2007-11-13 Teva Pharmacaetical Industries Ltd. Basic amine esters or oleic acid and their use as anti-inflammatory or immunobodulatory agents
MX2010007646A (es) * 2008-01-28 2010-08-03 Mead Johnson Nutrition Co Composicion nutritiva que contiene acido docosahexanoico, acido rumenico, y gangliosidos.
WO2012006612A2 (en) 2010-07-09 2012-01-12 President And Fellows Of Harvard College Use of trans-palmitoleate in identifying and treating metabolic disease
TWI650122B (zh) * 2012-07-09 2019-02-11 布萊恩霍頓視力協會 用於預防及/或治療乾眼症之組成物、方法及/或裝置
FR3011467B1 (fr) * 2013-10-08 2016-02-12 Centre Nat Rech Scient Composes et compositions comprenant de tels composes pour la prevention ou le traitement des dyslipidemies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2515174A1 (fr) 1981-10-23 1983-04-29 Roussel Uclaf Nouveaux triglycerides, procede de preparation et d'applications en dietetique et en therapeutique
US5231087A (en) * 1988-03-16 1993-07-27 Cellegy Pharmaceuticals, Inc. Treatment of skin diseases and tumors with esters and amides of monocarboxylic acids
JP3558351B2 (ja) * 1992-12-07 2004-08-25 邦郎 辻 免疫抑制剤
JPH06345644A (ja) * 1993-06-10 1994-12-20 Unitika Ltd 自己免疫性疾患治療剤
US5792774A (en) * 1996-02-21 1998-08-11 Chiroscience Limited Quinolones and their therapeutic use
US5683698A (en) * 1996-08-02 1997-11-04 New England Deaconess Hospital Formulation for alleviating symptoms associated with arthritis
WO2001003688A2 (en) 1999-07-09 2001-01-18 Pharmacia Corporation Treatment of cyclooxygenase-2 mediated disorders using conjugated fatty acid compounds
WO2001013956A2 (en) * 1999-08-26 2001-03-01 Ganeden Biotech, Inc. Use of emu oil a carrier for antifungal, antibacterial, and antiviral medications

Also Published As

Publication number Publication date
US20040186072A1 (en) 2004-09-23
ATE415157T1 (de) 2008-12-15
ES2321166T3 (es) 2009-06-03
IL158228A (en) 2009-12-24
WO2002083059A3 (en) 2004-10-07
US8614248B2 (en) 2013-12-24
AU2002255242A1 (en) 2002-10-28
WO2002083059A2 (en) 2002-10-24
DE60230067D1 (de) 2009-01-08
EP1480595A4 (en) 2005-05-11
EP1480595B1 (en) 2008-11-26
EP1480595A2 (en) 2004-12-01

Similar Documents

Publication Publication Date Title
IL142535A0 (en) Pharmaceutical compositions for the treatment of inflammation
IL142537A0 (en) Pharmaceutical compositions for the treatment of autoimmune diseases
SV1999000149A (es) 1,2,3,4 - tetrahidroquinolinas - 2 - metil - 4 - carboxiamino ref. pc10024/82736/bb
ES2179077T3 (es) Acido glutamico decarboxilasa clonada.
PT695759E (pt) Esteres metilicos de pentapeptidos inibidores de cancro humano
IL147556A0 (en) Pharmaceutical and nutritional compositions containing essential fatty acids and homocysteine-lowering agents
BR0112073A (pt) Combinações terapêuticas de ácidos graxos
BR9910639A (pt) Drogas anti-angiogênicas compreendendo peptìdeo
BR0313212A (pt) Aditivos de ácido de polialquileno glicol
HRP20041057A2 (en) Method and system for the esterification of fatty acids
ITRM930399A0 (it) Uso di esteri della l-carnitina o di acil l- carnitine con idrossiacidi per produrre composizioni farmaceutiche per il trattamento di affezioni cutanee.
GR3018691T3 (en) Amino acids, peptides or derivatives thereof coupled to fats
SE9602280D0 (sv) Immunstimulerande lipidformulering
WO2007148803A1 (ja) ヒアルロン酸産生促進能を有する組成物
MX2009005228A (es) Composiciones incrustadas en matriz que tienen acidos organicos y acidos grasos.
JP5054006B2 (ja) ヒアルロン酸産生促進能を有する組成物
PL332856A1 (en) Methods of and compositions for delivery and expression of nucleic acids as needed by interferon
WO1999059610A3 (de) Verwendung von lipopeptiden oder lipoproteinen zur wundbehandlung
ES2218714T3 (es) Peptido con dhc y agente que contiene este peptido.
EP2431029A3 (en) Method of inhibiting prostate cancer cell proliferation
GB2311533B (en) Esters of polyunsaturated fatty acids
NO996074D0 (no) Voksestere anriket i <omega>-3 umettede fettsyrer, deres fremstilling og deres anvendelse
AR043216A1 (es) Esteres activados de polietilenglicol
Levin et al. Kohki tea protects the rabbit bladder from ischemia/reperfusion-induced contractile dysfunction
RU2003125460A (ru) Биологически активный комплекс, содержащий фосфолипиды, для терапевтического использования